Marius Stan, MD
Endocrinology, Diabetes & Metabolism · Rochester, MNNPI 1679547103
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,982 of the $59,164 with a category attached, or 72.6%. 8 manufacturers reported payments, led by Argenx US, Inc. at 41.8% of the total. 2025 is the largest year on record at $33,363, 8.2 times the $4,088 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $1443.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$25K
- Amgen$19K
- Siemens Medical Solutions USA, Inc.$9K
- Genentech, Inc.$2K
- Ortho-clinical Diagnostics, Inc.$1K
- IBSA Institut Biochimique SA$1K
- plus $2K from 2 others
Across 29 payments — averaging $75,094 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.2M
- F. Hoffmann-la Roche AG$5K
- Otsuka Pharmaceutical Co., Ltd.$4K
What the payments were for
- Consulting fees$42,98273%
- Speaking & faculty fees$4,7418%
- Grants$6,02810%
- Travel & lodging$5,1699%
- Food & beverage$2450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 20 | $24,742 |
| Amgen(2 entities) | 9 | $19,201 |
| Siemens Medical Solutions USA, Inc. | 3 | $8,950 |
| Genentech, Inc. | 3 | $2,160 |
| Ortho-clinical Diagnostics, Inc. | 2 | $1,169 |
| IBSA Institut Biochimique SA | 1 | $1,091 |
| H. Lundbeck A S | 1 | $1,000 |
| Tolmar, Inc. | 2 | $850 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART HYTRULO$18,090
- TEPEZZA$10,039
- UPLIZNA$9,100
- ADVIA Immunoassay Reagents/Test Kit/Clinical Utilization$4,088
- VYVGART$3,000
- Atellica$2,613
- Atellica IM 1300 Analyzer$2,250
- VYEPTI$1,000
How this compares
$59,164 in reported general payments places this provider in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 160 | $2,022 |
| Methimazole | 33 | $448 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Rochester
- Marjorie Ann MalbasRochester$222K
- Irina BancosRochester$114K
- Maria CastroRochester$63K
- Matthew DrakeRochester$41K
- Manpreet MundiRochester$39K
- Yogish KudvaRochester$38K
- Bart ClarkeRochester$36K
- Robert RizzaRochester$30K
- Adrian VellaRochester$26K
- Michael JensenRochester$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.